14-day Premium Trial Subscription Try For FreeTry Free
NASDAQ:TSRO
Delisted

TESARO Fund Price (Quote)

$74.96
+0 (+0%)
At Close: Feb 13, 2019

Range Low Price High Price Comment
30 days $0.0060 $169.56 Wednesday, 13th Feb 2019 TSRO stock ended at $74.96. During the day the stock fluctuated 0% from a day low at $74.96 to a day high of $74.96.
90 days $113.65 $133.77
52 weeks $171.20 $133.77

Historical TESARO prices

Date Open High Low Close Volume
Oct 24, 2018 $35.95 $36.16 $30.13 $31.00 3 751 622
Oct 23, 2018 $36.05 $37.48 $33.06 $35.97 3 135 135
Oct 22, 2018 $42.02 $42.50 $36.81 $36.92 3 393 754
Oct 19, 2018 $43.31 $43.95 $41.07 $41.75 1 595 779
Oct 18, 2018 $44.00 $44.47 $42.78 $42.98 962 483
Oct 17, 2018 $43.32 $44.98 $42.89 $44.29 1 112 141
Oct 16, 2018 $41.71 $43.46 $41.45 $43.40 1 225 612
Oct 15, 2018 $40.38 $41.32 $39.37 $40.94 982 534
Oct 12, 2018 $39.50 $40.89 $38.80 $40.60 1 670 495
Oct 11, 2018 $40.30 $42.00 $38.49 $38.65 1 847 029
Oct 10, 2018 $42.34 $43.28 $40.71 $40.93 1 503 622
Oct 09, 2018 $41.90 $43.43 $41.51 $42.74 1 479 946
Oct 08, 2018 $42.25 $43.21 $41.51 $41.91 1 387 748
Oct 05, 2018 $41.75 $43.23 $41.75 $42.88 1 360 494
Oct 04, 2018 $41.42 $42.05 $40.32 $41.78 1 227 655
Oct 03, 2018 $40.01 $42.37 $39.64 $41.81 1 829 215
Oct 02, 2018 $38.88 $40.69 $38.88 $39.90 1 500 605
Oct 01, 2018 $39.55 $40.02 $38.76 $38.83 1 272 861
Sep 28, 2018 $38.27 $39.30 $38.05 $39.01 734 959
Sep 27, 2018 $38.19 $39.14 $37.58 $38.41 1 056 056
Sep 26, 2018 $37.49 $38.78 $37.19 $38.13 1 015 039
Sep 25, 2018 $37.15 $37.90 $36.43 $37.31 816 713
Sep 24, 2018 $37.63 $37.88 $35.82 $36.43 888 732
Sep 21, 2018 $37.81 $38.29 $37.16 $37.69 1 645 697
Sep 20, 2018 $36.95 $38.19 $35.85 $37.81 1 097 962
Click to get the best stock tips daily for free!

About TESARO

TESARO, Inc., an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States and internationally. Its product portfolio consist of Rolapitant, a neurokinin-1 receptor antagonist, which is in phase 1 intravenous clinical trials for the prevention of chemotherapy induced nausea and vomiting; Niraparib, an orally active and potent poly p... TSRO Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT